FDA advisory panel signals support for compounded peptide drugs

A US FDA panel is reported to have backed peptide compounding, a route to cheaper versions of scarce drugs.

According to the source's roundup, a US FDA advisory panel has come out in favor of allowing peptide compounding, which would let pharmacies prepare their own versions of certain drugs rather than relying solely on branded supply. The same briefing also touched on a Merck licensing deal for an HIV pill, though the detail there sits with the source.

Compounding matters for abundance because it opens a legal path around shortages and high prices. When a drug is scarce or expensive, the ability to compound a peptide equivalent can widen access for patients who would otherwise wait or pay more. It shifts supply from a single manufacturer toward many licensed preparers.

This is our read of a brief roundup item, and we could not reach the full source. A panel recommendation is not a final rule, and the specifics of scope, safety conditions, and which peptides qualify remain with the source's reporting. Treat this as a signal of direction, not a settled policy.

Source: STAT